A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Horn, L., Infante, J. R., Blumenschein, G. R., Wakelee, H. A., Arkenau, H., Dukart, G., Liang, C., Harrow, K., Gibbons, J., Lovly, C., Pao, W. AMER SOC CLINICAL ONCOLOGY. 2014

View details for Web of Science ID 000358613204095